查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2088760

CRISPR和Cas基因市場：按Cas類型、遞送方法、技術、應用和最終用戶分類－2026-2032年全球市場預測

CRISPR & Cas Genes Market by Cas Type, Delivery Method, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，CRISPR 和 Cas 基因市場將成長至 121.7 億美元，複合年成長率為 13.31%。

主要市場統計數據
基準年 2025 50.7億美元
預計年份：2026年 57.2億美元
預測年份 2032 121.7億美元
複合年成長率 (%) 13.31%

CRISPR和Cas基因技術已從基因組編輯的基礎發現發展成為具有重要商業性價值的平台，廣泛應用於包括人類治療、分子診斷、農業、功能基因組學和工業生物技術在內的許多領域。該領域的發展得益於可程式設計核酸酶（如Cas9、Cas12和Cas13）以及鹼基編輯、先導編輯和表觀基因編輯系統，這些系統旨在提高編輯精度、減少對雙鏈的依賴並擴大可編輯基因靶點的範圍。

在主要司法管轄區，基於 CRISPR 技術的鐮狀細胞疾病和輸血依賴型 BETA-地中海貧血藥物的批准進一步提升了其商業性信譽。這表明體外基因編輯技術能夠滿足嚴格的安全性、有效性和生產標準。學術機構、受託研究機構組織、生物技術開發公司、製藥公司、診斷檢測實驗室和農業研究中心正在拓展 CRISPR 工作流程，用於目標發現、細胞療法設計、疾病建模、作物性狀開發和快速核酸檢測。

CRISPR和Cas領域的變革性變化

CRISPR和Cas基因領域正從單一核酸酶研究工具轉向整合的基因組編輯生態系統，該系統結合了引導RNA設計、遞送化學、細胞處理、品質分析和符合法規的生產製造。這種轉變推動了對檢驗的試劑、高保真度酶、可擴展的病毒和非病毒遞送系統、自動化工作流程以及標準化脫靶評估方法的需求成長。

人工智慧對CRISPR技術的累積影響

人工智慧正在對整個CRISPR價值鏈產生累積影響。機器學習模型正在改進引導RNA的選擇、預測靶向編輯效率、評估脫靶活性並優先處理與疾病相關的變異，同時加速Cas酶的蛋白質工程改造，使其具有更高的特異性、緊湊性、耐熱性和靶向特異性。

CRISPR和Cas基因的關鍵區域性見解

北美憑藉其雄厚的生物技術資金、許多頂尖的學術醫療中心、先進的生物製造能力、活躍的臨床試驗基礎設施以及完善的細胞和基因療法監管體系，仍然是CRISPR和Cas基因領域的領先地區。美國是治療性基因編輯、功能基因組學、診斷和先進療法生產的核心驅動力，而加拿大則在基因組學研究、幹細胞科學、細胞療法生產以及公私合營醫療創新項目方面表現卓越。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東協地區，新加坡、泰國、馬來西亞、印尼、越南和菲律賓正在推動農業生物技術、感染疾病研究、水產養殖應用以及日益成長的生物醫學研發領域對CRISPR技術的需求。在海灣合作理事會國家，國家基因組學計劃、精準醫療投資、生物樣本庫建設和醫院現代化改造正在催生對基因組檢測、轉化研究、罕見疾病診斷和先進療法等領域夥伴關係的需求。

主要國家在 CRISPR 和 Cas 基因方面的趨勢

美國透過FDA監管的臨床計畫、生物技術資金、基因組學基礎設施以及緊密的研究機構和先進治療藥物製造地網路，引領CRISPR技術的商業化進程。加拿大在幹細胞研究、細胞療法、基因組學舉措和健康數據基礎設施方面擁有優勢，而墨西哥則日益重視轉化基因組學和區域生產。巴西是拉丁美洲農業生物技術領域最具影響力的市場，並正在擴大其在感染疾病、基因組學和公共衛生領域的生物醫學研究能力。

為行業領導者提供的實用建議

產業領導者應優先考慮CRISPR技術在臨床應用方面展現出明顯優勢的領域，例如持續糾正單基因疾病、基因修飾免疫細胞、檢驗功能基因組學、快速分子診斷以及靶向作物性狀改良。產品組合決策應基於實施可行性、編輯產品的永續性、可生產性、與支付方（保險公司）的相關性、與臨床工作流程的契合度、生物安全要求以及合理的智慧財產權。

調查方法

本執行摘要基於一個整合了公開監管決策、同行評審科學文獻、臨床試驗註冊資訊、專利出版物、政府基因組學舉措、生物倫理指南以及已建立的生物技術和生命科學資料庫的二級研究框架。它重點關注檢驗的進展，包括已通過核准的基於 CRISPR 的療法、已確認的 Cas 酶類別、已記錄的區域生物技術能力以及已發表的關於遞送、特異性和安全性評估的證據。

結論

CRISPR和Cas基因市場正進入一個更嚴格的階段，不僅需要強大的科學實力，還需要臨床檢驗、遞送技術的創新、生產規模、倫理監管和負責任的管治。儘管監管部門的批准已經證實了這些平台的治療潛力，但長期的市場領先地位取決於安全性證據、持續的臨床療效、可及性模式以及針對特定應用情境的執行。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：CRISPR和Cas基因市場：依Cas類型分類

  • Cas12
  • Cas13
  • Cas14
  • Cas9

第8章：CRISPR和Cas基因市場：按遞送方式分類

  • 電穿孔
  • 脂質體轉染
  • 顯微注射
  • 奈米顆粒遞送方法
    • 脂質奈米顆粒
    • 聚合物奈米粒子
  • 病毒載體
    • 腺結合病毒
    • 腺病毒
    • 慢病毒

第9章：CRISPR和Cas基因市場：按技術分類

  • Ex Vivo
    • 細胞株工程
    • 原始細胞的改造
  • 體內
    • 臨床試驗
    • 臨床前模型

第10章：CRISPR和Cas基因市場：按應用領域分類

  • 農業生物技術
  • 動物模型的發展
  • 診斷
    • 疾病檢測
    • 基因篩檢
  • 基因編輯
    • 出於研究目的
    • 治療用途
  • 基因治療

第11章：CRISPR和Cas基因市場：按最終用戶分類

  • 生技公司
  • 受託研究機構
  • 製藥公司
  • 研究機構

第12章：CRISPR和Cas基因市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：CRISPR和Cas基因市場：按組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：CRISPR和Cas基因市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Addgene
  • AstraZeneca PLC
  • Bayer AG
  • Beam Therapeutics Inc.
  • Beckman Coulter, Inc.
  • Calyxt, Inc.
  • Caribou Biosciences, Inc.
  • Cellectis plant sciences, Inc.
  • Corteva, Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • GenScript Biotech Corporation
  • Hera Biolabs
  • Inscripta, Inc.
  • Integrated DNA Technologies, Inc.
  • Intellia Therapeutics, Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences, Inc.
  • Merck KGaA
  • OriGene Technologies, Inc.
  • PerkinElmer, Inc.
  • Sangamo Therapeutics, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5642D503D83C

The CRISPR & Cas Genes Market is projected to grow by USD 12.17 billion at a CAGR of 13.31% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.07 billion
Estimated Year [2026] USD 5.72 billion
Forecast Year [2032] USD 12.17 billion
CAGR (%) 13.31%

CRISPR and Cas genes have advanced from a foundational genome-editing discovery to a commercially relevant platform used across human therapeutics, molecular diagnostics, agriculture, functional genomics, and industrial biotechnology. The field is anchored by programmable nucleases such as Cas9, Cas12, and Cas13, along with base-editing, prime-editing, and epigenome-editing systems designed to improve precision, reduce double-strand break dependency, and expand the range of actionable genetic targets.

Commercial confidence strengthened after regulatory approvals of CRISPR-based medicines for sickle cell disease and transfusion-dependent beta thalassemia in major jurisdictions, validating that ex vivo gene editing can meet rigorous safety, efficacy, and manufacturing standards. Academic institutes, contract research organizations, biotechnology developers, pharmaceutical manufacturers, diagnostic laboratories, and agricultural research centers are expanding CRISPR workflows for target discovery, cell therapy engineering, disease modeling, crop trait development, and rapid nucleic acid detection.

Transformative Shifts in the CRISPR & Cas Landscape

The CRISPR and Cas genes landscape is shifting from single-nuclease research tools toward integrated genome-editing ecosystems that combine guide RNA design, delivery chemistry, cell processing, quality analytics, and regulatory-grade manufacturing. This transition is increasing demand for validated reagents, high-fidelity enzymes, scalable viral and non-viral delivery systems, automation-compatible workflows, and standardized off-target assessment methods.

A second transformation is the move beyond ex vivo hematology into in vivo editing, immuno-oncology, rare disease programs, regenerative medicine, crop trait development, antimicrobial research, and point-of-care diagnostics. Adoption remains shaped by delivery limitations, immune response monitoring, off-target risk management, intellectual property complexity, reimbursement readiness, biosecurity considerations, and jurisdiction-specific rules for human, animal, and agricultural genome editing.

Cumulative Impact of Artificial Intelligence on CRISPR

Artificial intelligence is becoming a cumulative force across the CRISPR value chain. Machine learning models are improving guide RNA selection, predicting on-target editing efficiency, estimating off-target activity, prioritizing disease-associated variants, and accelerating protein engineering for Cas enzymes with improved specificity, compactness, temperature tolerance, and targeting properties.

AI is also supporting experimental design, image-based phenotyping, single-cell and multi-omics analysis, clinical candidate prioritization, and manufacturing quality control. The strongest near-term value is emerging where AI is paired with high-quality wet-lab datasets, validated assays, standardized metadata, and transparent model governance, because regulators, clinicians, and research partners require reproducible evidence rather than algorithmic claims alone.

Key Regional Insights for CRISPR & Cas Genes

North America remains a leading region for CRISPR and Cas genes due to deep biotechnology financing, major academic medical centers, advanced biomanufacturing capacity, active clinical trial infrastructure, and established regulatory pathways for cell and gene therapies. The United States is the core engine for therapeutic gene editing, functional genomics, diagnostics, and advanced therapy manufacturing, while Canada contributes strengths in genomics research, stem cell science, cell therapy production, and public-private health innovation programs.

Europe is defined by strong biomedical science, coordinated medicines regulation, and notable adoption in advanced therapy medicinal products, with the European Union providing structured clinical evaluation, pharmacovigilance, and post-authorization oversight. The United Kingdom, Germany, France, Italy, and Spain support research translation through university hospitals, national genomics initiatives, clinical networks, diagnostics capabilities, and biopharma clusters focused on rare diseases, oncology, regenerative medicine, and advanced therapies.

Asia-Pacific is scaling rapidly, led by China, Japan, South Korea, India, Australia, and ASEAN economies that are investing in genomics, clinical development, agricultural biotechnology, and biomanufacturing infrastructure. Latin America is emerging through Brazil and Mexico, where infectious disease research, crop science, and academic genomics capacity are expanding. The Middle East is building genomics-led healthcare and precision medicine strategies through Gulf investments, while Africa's opportunity is tied to capacity building, infectious disease diagnostics, food security, local research infrastructure, and equitable access to genome-editing tools.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

Within ASEAN, CRISPR demand is supported by agricultural biotechnology, infectious disease research, aquaculture applications, and rising biomedical R&D across Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries are using national genomics programs, precision medicine investments, biobank development, and hospital modernization to create demand for genomic testing, translational research, rare disease diagnostics, and advanced therapy partnerships.

The European Union remains central to regulatory harmonization, clinical trial oversight, data protection standards, and advanced therapy development, making it a key reference environment for compliance-led CRISPR commercialization. BRICS economies combine large patient populations, agricultural productivity needs, expanding scientific capacity, and growing biomanufacturing infrastructure, creating sustained demand across healthcare, diagnostics, livestock improvement, and crop trait development.

G7 markets set the pace for intellectual property activity, reimbursement evaluation, clinical adoption, ethical governance, and manufacturing standards, while NATO-aligned countries benefit from strong biomedical security, pathogen surveillance, dual-use governance frameworks, and coordinated research security priorities. Across these groups, the most successful participants are those that align product claims, clinical evidence, data packages, biosafety practices, and market access strategies with local policy priorities.

Key Country Insights for CRISPR & Cas Genes

The United States leads CRISPR commercialization through FDA-regulated clinical programs, biotechnology financing, genomic medicine infrastructure, and a dense network of research institutions and advanced therapy manufacturing sites. Canada adds strengths in stem cell research, cell therapy, genomics initiatives, and health data infrastructure, while Mexico is developing translational genomics and regional manufacturing relevance. Brazil is the most influential Latin American market for agricultural biotechnology and is expanding biomedical research capacity in infectious disease, genomics, and public health applications.

In Europe, the United Kingdom has been an early regulator of CRISPR-based therapy and maintains strong genomics infrastructure, clinical research networks, and advanced therapy capabilities. Germany and France provide mature biopharma, diagnostics, academic research, and manufacturing ecosystems, while Italy and Spain contribute hospital-based clinical networks and growing advanced therapy capacity. Russia maintains scientific expertise in molecular biology and genetics, although international collaboration, procurement, and market access are affected by geopolitical and regulatory constraints.

China is a major force in CRISPR research output, clinical exploration, agricultural biotechnology, and manufacturing scale. India is expanding through cost-efficient research services, vaccine and biopharma capabilities, genomics programs, and agricultural biotechnology needs. Japan emphasizes high-quality translational science, regenerative medicine frameworks, and precision healthcare, while Australia supports clinical research, genomics implementation, and agricultural innovation. South Korea combines strong biotechnology investment, digital health infrastructure, and advanced cell and gene therapy capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically meaningful applications where CRISPR offers clear advantages over conventional approaches, including durable correction of monogenic disease, engineered immune cells, validated functional genomics, rapid molecular diagnostics, and targeted crop trait improvement. Portfolio decisions should be guided by delivery feasibility, edit durability, manufacturability, payer relevance, clinical workflow fit, biosafety requirements, and defensible intellectual property.

Organizations should invest in high-fidelity editing systems, validated off-target and on-target assessment, scalable GMP manufacturing, robust release testing, and AI-supported design platforms with transparent data governance. Partnerships with academic medical centers, contract development and manufacturing organizations, diagnostic laboratories, agricultural institutes, patient groups, and regional regulatory experts can shorten development timelines while reducing technical, compliance, and access-related risks.

Research Methodology

This executive summary is developed using a secondary research framework that synthesizes public regulatory decisions, peer-reviewed scientific literature, clinical trial registries, patent publications, government genomics initiatives, bioethics guidance, and established biotechnology and life sciences databases. Emphasis is placed on verifiable developments, including approved CRISPR-based therapies, recognized Cas enzyme classes, documented regional biotechnology capabilities, and published evidence on delivery, specificity, and safety assessment.

Insights are triangulated across technology, application, end-user, regulatory environment, and geography to identify market direction without relying on unsupported claims. The methodology prioritizes data integrity, regulatory relevance, reproducibility, scientific consensus, and practical commercial interpretation for decision-makers in biotechnology, pharmaceuticals, diagnostics, agriculture, research tools, and advanced therapy manufacturing.

Conclusion

The CRISPR and Cas genes market is entering a more disciplined phase in which scientific capability must be matched by clinical validation, delivery innovation, manufacturing scale, ethical oversight, and responsible governance. Regulatory approvals have confirmed the platform's therapeutic potential, but long-term leadership will depend on safety evidence, durable clinical outcomes, access models, and application-specific execution.

Organizations that combine robust genome-editing science with AI-enabled discovery, regional regulatory intelligence, scalable manufacturing, and transparent risk management will be best positioned to capture value. The next wave of development will be shaped by in vivo editing, next-generation Cas systems, precision diagnostics, multiplex functional genomics, and expanded use in agriculture and industrial biotechnology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. CRISPR & Cas Genes Market, by Cas Type

  • 7.1. Cas12
  • 7.2. Cas13
  • 7.3. Cas14
  • 7.4. Cas9

8. CRISPR & Cas Genes Market, by Delivery Method

  • 8.1. Electroporation
  • 8.2. Liposome Transfection
  • 8.3. Microinjection
  • 8.4. Nanoparticle Delivery
    • 8.4.1. Lipid Nanoparticles
    • 8.4.2. Polymer Nanoparticles
  • 8.5. Viral Vector
    • 8.5.1. Adeno Associated Virus
    • 8.5.2. Adenovirus
    • 8.5.3. Lentivirus

9. CRISPR & Cas Genes Market, by Technology

  • 9.1. Ex Vivo
    • 9.1.1. Cell Line Engineering
    • 9.1.2. Primary Cell Modification
  • 9.2. In Vivo
    • 9.2.1. Clinical Trials
    • 9.2.2. Preclinical Models

10. CRISPR & Cas Genes Market, by Application

  • 10.1. Agricultural Biotechnology
  • 10.2. Animal Model Development
  • 10.3. Diagnostics
    • 10.3.1. Disease Detection
    • 10.3.2. Genetic Screening
  • 10.4. Gene Editing
    • 10.4.1. Research Applications
    • 10.4.2. Therapeutic Applications
  • 10.5. Gene Therapy

11. CRISPR & Cas Genes Market, by End User

  • 11.1. Biotechnology Companies
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Institutes

12. CRISPR & Cas Genes Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. CRISPR & Cas Genes Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. CRISPR & Cas Genes Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Addgene
  • 16.2. AstraZeneca PLC
  • 16.3. Bayer AG
  • 16.4. Beam Therapeutics Inc.
  • 16.5. Beckman Coulter, Inc.
  • 16.6. Calyxt, Inc.
  • 16.7. Caribou Biosciences, Inc.
  • 16.8. Cellectis plant sciences, Inc.
  • 16.9. Corteva, Inc.
  • 16.10. CRISPR Therapeutics AG
  • 16.11. Danaher Corporation
  • 16.12. Editas Medicine, Inc.
  • 16.13. GenScript Biotech Corporation
  • 16.14. Hera Biolabs
  • 16.15. Inscripta, Inc.
  • 16.16. Integrated DNA Technologies, Inc.
  • 16.17. Intellia Therapeutics, Inc.
  • 16.18. Lonza Group Ltd.
  • 16.19. Mammoth Biosciences, Inc.
  • 16.20. Merck KGaA
  • 16.21. OriGene Technologies, Inc.
  • 16.22. PerkinElmer, Inc.
  • 16.23. Sangamo Therapeutics, Inc.
  • 16.24. Takara Bio Inc.
  • 16.25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CRISPR & CAS GENES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CRISPR & CAS GENES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CRISPR & CAS GENES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CRISPR & CAS GENES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CRISPR & CAS GENES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CRISPR & CAS GENES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CAS12 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CAS12 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CAS12 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CAS13 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CAS13 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CAS13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CAS14 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CAS14 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CAS14 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CAS9 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CAS9 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CAS9 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ELECTROPORATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ELECTROPORATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ELECTROPORATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIPOSOME TRANSFECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIPOSOME TRANSFECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIPOSOME TRANSFECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MICROINJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MICROINJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MICROINJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NANOPARTICLE DELIVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NANOPARTICLE DELIVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NANOPARTICLE DELIVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIPID NANOPARTICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POLYMER NANOPARTICLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POLYMER NANOPARTICLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POLYMER NANOPARTICLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADENO ASSOCIATED VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADENO ASSOCIATED VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADENO ASSOCIATED VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADENOVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADENOVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ADENOVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LENTIVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LENTIVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LENTIVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EX VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EX VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EX VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CELL LINE ENGINEERING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL LINE ENGINEERING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL LINE ENGINEERING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PRIMARY CELL MODIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PRIMARY CELL MODIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRIMARY CELL MODIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IN VIVO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IN VIVO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IN VIVO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PRECLINICAL MODELS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRECLINICAL MODELS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PRECLINICAL MODELS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AGRICULTURAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL MODEL DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL MODEL DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL MODEL DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DISEASE DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DISEASE DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DISEASE DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENETIC SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENETIC SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENETIC SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENE EDITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENE EDITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RESEARCH APPLICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL THERAPEUTIC APPLICATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL THERAPEUTIC APPLICATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL THERAPEUTIC APPLICATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. GCC CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 195. GCC CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 196. GCC CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 197. GCC CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 199. GCC CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 200. GCC CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 203. GCC CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. G7 CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. G7 CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 231. G7 CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 232. G7 CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 233. G7 CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 235. G7 CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 236. G7 CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. G7 CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 239. G7 CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. NATO CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. NATO CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. NATO CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 243. NATO CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 244. NATO CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 245. NATO CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 247. NATO CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 248. NATO CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. NATO CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 251. NATO CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL CRISPR & CAS GENES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. CANADA CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. CANADA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. CANADA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 268. CANADA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 269. CANADA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 270. CANADA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. CANADA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 272. CANADA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 273. CANADA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. CANADA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 275. CANADA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 276. CANADA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. MEXICO CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. MEXICO CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. MEXICO CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 280. MEXICO CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 281. MEXICO CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 282. MEXICO CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. MEXICO CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 284. MEXICO CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 285. MEXICO CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 286. MEXICO CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 287. MEXICO CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 288. MEXICO CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. BRAZIL CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 292. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 293. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 294. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 296. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 297. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 299. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 300. BRAZIL CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED KINGDOM CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. GERMANY CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. GERMANY CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. GERMANY CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 316. GERMANY CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 317. GERMANY CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 318. GERMANY CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. GERMANY CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 320. GERMANY CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 321. GERMANY CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 322. GERMANY CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 323. GERMANY CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 324. GERMANY CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. FRANCE CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. FRANCE CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. FRANCE CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 328. FRANCE CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 329. FRANCE CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 330. FRANCE CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. FRANCE CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 332. FRANCE CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 333. FRANCE CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 334. FRANCE CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 335. FRANCE CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 336. FRANCE CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 337. RUSSIA CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 338. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 340. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 341. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 342. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 343. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 344. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 345. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 346. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 347. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 348. RUSSIA CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 349. ITALY CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 350. ITALY CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 351. ITALY CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 352. ITALY CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 353. ITALY CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 354. ITALY CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 355. ITALY CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 356. ITALY CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 357. ITALY CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 358. ITALY CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 359. ITALY CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 360. ITALY CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 361. SPAIN CRISPR & CAS GENES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 362. SPAIN CRISPR & CAS GENES MARKET SIZE, BY CAS TYPE, 2018-2032 (USD MILLION)
  • TABLE 363. SPAIN CRISPR & CAS GENES MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 364. SPAIN CRISPR & CAS GENES MARKET SIZE, BY NANOPARTICLE DELIVERY, 2018-2032 (USD MILLION)
  • TABLE 365. SPAIN CRISPR & CAS GENES MARKET SIZE, BY VIRAL VECTOR, 2018-2032 (USD MILLION)
  • TABLE 366. SPAIN CRISPR & CAS GENES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 367. SPAIN CRISPR & CAS GENES MARKET SIZE, BY EX VIVO, 2018-2032 (USD MILLION)
  • TABLE 368. SPAIN CRISPR & CAS GENES MARKET SIZE, BY IN VIVO, 2018-2032 (USD MILLION)
  • TABLE 369. SPAIN CRISPR & CAS GENES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 370. SPAIN CRISPR & CAS GENES MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 371. SPAIN CRISPR & CAS GENES MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 372. SPAIN CRISPR & CAS GENES MARKET SIZE, BY END USER, 2018-2032 (U